Medrobotics today released data from an 80-patient post-market study of its Flex robotic system, touting the system as a “safe and effective tool in transoral robotic surgery.”
The Flex robotic system is designed to use a flexible robotic endoscope, a range of flexible instruments and a high-definition vision system for use in accessing and visualizing structures in the mouth and throat.
The study, which examined patients at 3 hospitals in Germany and 1 in Belgium, aimed to analyze the safety and effectiveness of the Flex system when used by surgeons to treat benign and malignant lesions in the throat.
“My colleagues and I performed the world’s 1st robotic-assisted cancer procedures with the Medrobotics Flex Robotic System 2 years ago. The technology has continually improved since then, allowing us better access to challenging surgical sites. This unique, flexible system offers a number of surgical advantages over linear robot systems that move in straight lines. The most obvious one is it can navigate the body’s natural curves,” study presenter Dr. Stephen Lang said in a press release.
Study data indicated that the system was able to successfully visualize and access the target area in 94% of cases, with 91% enjoying successful biopsies.
A total 58% of the procedures were performed in areas the surgeons considered “difficult to reach,” such as the tongue base and vocal chords, the company said. No device-related adverse events were reported, the company said.
Last November, Medrobotics said that it raised a $25 million equity round for its Flex robotic endoscope system.
A month prior, Raynham, Mass.-based Medrobotics reported raising the 1st $2.4 million of the round.
Last July, Medrobotics said it won FDA 510(k) clearance for the Flex system and was planning a U.S. launch. The company said it plans to use the proceeds from the funding round to expand its commercial reach.